All News

Language preference significantly impacts access to continuous glucose monitors for type 2 diabetes, revealing critical disparities in diabetes care.

Elinzanetant, the first FDA-approved nonhormonal treatment for menopause-related vasomotor symptoms, offers women a new, effective relief option.

Revumenib was approved for adults and pediatric patients 1 year and older with relapsed or refractory acute myeloid leukemia.

Explore the promising data on elinzanetant for managing menopause-related vasomotor symptoms, highlighting its tolerability and minimal side effects.

A heightened ratio of non-high-density lipoprotein cholesterol (non-HDL-C) to HDL-C was associated with depression, with risk mediated by body mass index.

This quiz was created in collaboration with PTCE™.

The authors wrote that their findings show a necessary update following early data from the Women’s Health Initiative.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

Samantha Picking, PharmD, highlights pharmacists’ leadership in immunization initiatives, public health collaborations, and the evolving role of community pharmacy in preventive care.

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma, enhancing treatment options and survival rates for patients with limited therapies.

If approved, SYD-101 would have been the first FDA-approved treatment for pediatric myopia, offering hope to millions of affected children in the US.

New research highlights the enhanced humoral response in lymphoma survivors receiving two doses of the PCV20 vaccine, emphasizing vaccination's critical role in infection prevention.

Megan Dulohery Scrodin, MD, highlights Mayo Clinic's innovative COPD care model, emphasizing multidisciplinary collaboration and AI tools for improved patient outcomes.

Initiatives aim to reduce residents' high rates of depression and increase self-care skills.

Experts discuss breakthroughs in respiratory virus vaccines.

Elinzanetant shows promise as a new treatment for menopause-related vasomotor symptoms, offering rapid relief and a favorable safety profile.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.

Clear communication, personalized counseling, and supportive environments help address barriers, empower patients, and enhance outcomes.

Pharmacy students face emotional struggles but require resilience, shared support, and love to move forward.

Although long COVID remains a complex disease, pharmacists are critical team members for patient symptom validation, managing polypharmacy, and navigating therapy access.

Research highlights the impact of sleep disturbances and vasomotor symptoms (VMS) on HRQoL in women transitioning to menopausal period, emphasizing the need for effective management.

Embedding standards in pharmacy practice help ensure medication quality, safety, and patient understanding.

Research reveals varying impacts of GLP-1 receptor agonists on asthma risk, urging careful medication selection for patients with diabetes and respiratory issues.

Explore how pharmacists can better support indigenous and Hispanic women during menopause through culturally sensitive care and family involvement.

When administering T-cell–modifying therapies, infections during and after treatment are a serious and pertinent risk.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.